세계의 노인황반변성 시장 보고서(2025년)

Age-related macular degeneration (AMD) is a progressive eye condition characterized by the deterioration of the macula, located at the center of the retina, resulting in a gradual loss of central vision due to aging. Therapeutic options for AMD encompass regular eye examinations, lifestyle modifications, and specific nutritional supplements.

There are two main types of age-related macular degeneration, wet age-related macular degeneration (AMD) and dry age-related macular degeneration (AMD). Wet AMD is a progressive eye disease marked by the growth of abnormal blood vessels beneath the macula, the central part of the retina responsible for sharp, central vision. Treatment for wet AMD involves the use of various drugs such as Eylea, Lucentis, Avastin, and others. These drugs are administered through intravenous and intravitreal routes and are typically dispensed through hospital pharmacies, specialty pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The age-related macular degeneration market research report is one of a series of new reports from The Business Research Company that provides age-related macular degeneration market statistics, including age-related macular degeneration industry global market size, regional shares, competitors with an age-related macular degeneration market share, detailed age-related macular degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the age-related macular degeneration industry. This age-related macular degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The age-related macular degeneration market size has grown strongly in recent years. It will grow from $9.96 billion in 2024 to $10.67 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to aging population demographics, changing lifestyles and environmental factors, genetic predisposition, increased awareness and early diagnosis, advancements in diagnostic techniques.

The age-related macular degeneration market size is expected to see strong growth in the next few years. It will grow to $14.29 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to research in genetics and biomarkers, emerging therapeutic modalities, telemedicine and remote monitoring, patient advocacy and education. Major trends in the forecast period include personalized medicine approaches, innovations in retinal imaging technologies, emergence of sustained drug delivery systems, clinical trials for investigational therapies, collaborations for research and development.

The forecast of 7.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. ophthalmology by restricting access to anti-Vascular Endothelial Growth Factor(VEGF) biologics and optical coherence tomography (OCT) machines imported from Germany and the Netherlands, potentially worsening vision preservation outcomes and increasing retinal specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in the age-related macular degeneration (AMD) market is expected to be driven by the increasing prevalence of AMD, a progressive eye condition that affects the macula, a crucial part of the retina responsible for central vision. Treatments for age-related macular degeneration aim to mitigate the severity of the disease, and the rising prevalence of AMD is a significant factor contributing to market growth. According to reports from Optimaxa, a UK-based laser eye treatment specialist, as of February 2023, approximately 196 million individuals worldwide are affected by age-related macular degeneration (AMD), with projections estimating a rise to 288 million by 2040. This would account for 8.7 percent of the global population. The escalating prevalence of AMD underscores the need for effective treatments and is a key driver for the growth of the age-related macular degeneration market.

The expanding aging population is anticipated to boost the growth of the age-related macular degeneration (AMD) market in the coming years. The term "aging population" describes a demographic shift characterized by an increasing proportion or number of individuals aged 65 years and older within a society. As the global elderly population rises, there is also a corresponding increase in the prevalence of AMD, a progressive eye condition that affects central vision. For example, in January 2024, the Population Reference Bureau, a U.S.-based nonprofit organization, projected that the number of Americans aged 65 and older will increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. Additionally, the share of this age group in the total population is expected to grow from 17% to 23% during the same period. Consequently, the increasing aging population is a key factor driving the growth of the age-related macular degeneration market.

Leading companies in the age-related macular degeneration (AMD) market are focusing on developing innovative treatments, such as bispecific antibodies, to reduce the frequency of treatments. A bispecific antibody is an engineered antibody that can bind to two different antigens at the same time. For example, in May 2022, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Vabysmo intravitreal injection 120 mg/mL, a bispecific antibody aimed at treating eye conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). This innovative therapy works by simultaneously targeting two critical pathways: angiopoietin-2 (Ang-2), which plays a role in abnormal blood vessel growth and inflammation, and Vascular Endothelial Growth Factor-A (VEGF-A), a key factor in the formation of new blood vessels that can result in vision loss. A significant advantage of Vabysmo is its extended dosing intervals, allowing treatments to be given every 16 weeks, thereby improving patient convenience and adherence. Its dual-action mechanism represents a major advancement in ophthalmic treatments, effectively meeting the urgent need for dependable therapies in retinal diseases.

Key players in the age-related macular degeneration (AMD) market are advancing innovative technologies, such as recombinant antigen-binding fragments. These recombinant antigen-binding fragments (Fab) are engineered proteins derived from antibodies that specifically target and bind to certain antigens, and are often used therapeutically to inhibit disease-related pathways. For example, in December 2023, Enzene Biosciences, a biotechnology company based in India, launched ranibizumab, a recombinant monoclonal antibody fragment (Fab) specifically designed to inhibit vascular endothelial growth factor (VEGF), a critical protein involved in the formation of abnormal blood vessels in conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). By blocking VEGF, ranibizumab effectively reduces the leakage and proliferation of these blood vessels, helping to preserve vision in patients suffering from these retinal disorders. Administered through intravitreal injection, ranibizumab has become widely accepted in clinical practice due to its effectiveness in treating various retinal diseases. Its introduction has significantly improved the treatment landscape for patients dealing with these serious conditions.

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. Through this acquisition, Astellas Pharma aims to expand its presence in the ophthalmology market and accelerate the development of novel treatments for age-related macular degeneration. IVERIC Bio Inc., a US-based biotech corporation, specializes in the development of drugs and products for treating age-related macular degeneration, making it a strategic addition to Astellas Pharma's portfolio in the ophthalmology sector.

Major companies operating in the age-related macular degeneration market include F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

North America was the largest region in the global age-related macular degeneration market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the age-related macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The age-related macular degeneration market consists of sales of anti-vascular endothelial growth factor (anti-VEGF) drugs, photodynamic therapy (PDT), low-vision aids, and telescopic lenses. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Age-Related Macular Degeneration Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on age-related macular degeneration market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for age-related macular degeneration ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The age-related macular degeneration market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Wet Age-Related Macular Degeneration (AMD); Dry Age-Related Macular Degeneration (AMD)
• 2) By Drug: Eylea; Lucentis; Avastin; Other Products
• 3) By Route Of Administration: Intravenous; Intravitreal
• 4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections; Photodynamic Therapy; Laser Surgery
• 2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements; Low Vision Aids; Therapies For Geographic Atrophy
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; Bayer AG; Pfizer Inc.; Bausch Health Companies Inc.; Regeneron Pharmaceuticals Inc.; Amgen Inc.; Alimera Sciences Inc.; Alkeus Pharmaceuticals Inc.; AbbVie Inc.; Outlook Therapeutics Inc.; Biogen Inc.; Samsung Bioepis Co. Ltd.; Biocon Ltd.; Bio-Thera Biopharmaceutical Co. Ltd.; AstraZeneca plc; Acucela Inc.; Ophthotech Corporation; Kodiak Sciences Inc.; REGENXBIO Inc.; Alkahest Inc.; Opthea Limited; Apellis Pharmaceuticals Inc.; Graybug Vision Inc.; IVERIC bio Inc.; Santen Pharmaceutical Co. Ltd.; Ocular Therapeutix Inc.; Tyrogenex Inc.; Chengdu Kanghong Pharmaceutical Group Co. Ltd.; I-Mab Biopharma Co. Ltd.; pSivida Corp.; Clearside Biomedical Inc.; SciFluor Life Sciences LLC; Lineage Cell Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Age-Related Macular Degeneration Market Characteristics

3. Age-Related Macular Degeneration Market Trends And Strategies

4. Age-Related Macular Degeneration Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Age-Related Macular Degeneration Growth Analysis And Strategic Analysis Framework

• 5.1. Global Age-Related Macular Degeneration PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Age-Related Macular Degeneration Market Growth Rate Analysis
• 5.4. Global Age-Related Macular Degeneration Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Age-Related Macular Degeneration Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Age-Related Macular Degeneration Total Addressable Market (TAM)

6. Age-Related Macular Degeneration Market Segmentation

• 6.1. Global Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wet Age-Related Macular Degeneration (AMD)
• Dry Age-Related Macular Degeneration (AMD)
• 6.2. Global Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eylea
• Lucentis
• Avastin
• Other Products
• 6.3. Global Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Intravitreal
• 6.4. Global Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Specialty Pharmacy
• Online Pharmacy
• 6.5. Global Age-Related Macular Degeneration Market, Sub-Segmentation Of Wet Age-Related Macular Degeneration (AMD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-VEGF Injections
• Photodynamic Therapy
• Laser Surgery
• 6.6. Global Age-Related Macular Degeneration Market, Sub-Segmentation Of Dry Age-Related Macular Degeneration (AMD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Supplements
• Low Vision Aids
• Therapies For Geographic Atrophy

7. Age-Related Macular Degeneration Market Regional And Country Analysis

• 7.1. Global Age-Related Macular Degeneration Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Age-Related Macular Degeneration Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Age-Related Macular Degeneration Market

• 8.1. Asia-Pacific Age-Related Macular Degeneration Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Age-Related Macular Degeneration Market

• 9.1. China Age-Related Macular Degeneration Market Overview
• 9.2. China Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Age-Related Macular Degeneration Market

• 10.1. India Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Age-Related Macular Degeneration Market

• 11.1. Japan Age-Related Macular Degeneration Market Overview
• 11.2. Japan Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Age-Related Macular Degeneration Market

• 12.1. Australia Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Age-Related Macular Degeneration Market

• 13.1. Indonesia Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Age-Related Macular Degeneration Market

• 14.1. South Korea Age-Related Macular Degeneration Market Overview
• 14.2. South Korea Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Age-Related Macular Degeneration Market

• 15.1. Western Europe Age-Related Macular Degeneration Market Overview
• 15.2. Western Europe Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Age-Related Macular Degeneration Market

• 16.1. UK Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Age-Related Macular Degeneration Market

• 17.1. Germany Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Age-Related Macular Degeneration Market

• 18.1. France Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Age-Related Macular Degeneration Market

• 19.1. Italy Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Age-Related Macular Degeneration Market

• 20.1. Spain Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Age-Related Macular Degeneration Market

• 21.1. Eastern Europe Age-Related Macular Degeneration Market Overview
• 21.2. Eastern Europe Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Age-Related Macular Degeneration Market

• 22.1. Russia Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Age-Related Macular Degeneration Market

• 23.1. North America Age-Related Macular Degeneration Market Overview
• 23.2. North America Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Age-Related Macular Degeneration Market

• 24.1. USA Age-Related Macular Degeneration Market Overview
• 24.2. USA Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Age-Related Macular Degeneration Market

• 25.1. Canada Age-Related Macular Degeneration Market Overview
• 25.2. Canada Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Age-Related Macular Degeneration Market

• 26.1. South America Age-Related Macular Degeneration Market Overview
• 26.2. South America Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Age-Related Macular Degeneration Market

• 27.1. Brazil Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Age-Related Macular Degeneration Market

• 28.1. Middle East Age-Related Macular Degeneration Market Overview
• 28.2. Middle East Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Age-Related Macular Degeneration Market

• 29.1. Africa Age-Related Macular Degeneration Market Overview
• 29.2. Africa Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Age-Related Macular Degeneration Market Competitive Landscape And Company Profiles

• 30.1. Age-Related Macular Degeneration Market Competitive Landscape
• 30.2. Age-Related Macular Degeneration Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Age-Related Macular Degeneration Market Other Major And Innovative Companies

• 31.1. Regeneron Pharmaceuticals Inc.
• 31.2. Amgen Inc.
• 31.3. Alimera Sciences Inc.
• 31.4. Alkeus Pharmaceuticals Inc.
• 31.5. AbbVie Inc.
• 31.6. Outlook Therapeutics Inc.
• 31.7. Biogen Inc.
• 31.8. Samsung Bioepis Co. Ltd.
• 31.9. Biocon Ltd.
• 31.10. Bio-Thera Biopharmaceutical Co. Ltd.
• 31.11. AstraZeneca plc
• 31.12. Acucela Inc.
• 31.13. Ophthotech Corporation
• 31.14. Kodiak Sciences Inc.
• 31.15. REGENXBIO Inc.

32. Global Age-Related Macular Degeneration Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Age-Related Macular Degeneration Market

34. Recent Developments In The Age-Related Macular Degeneration Market

35. Age-Related Macular Degeneration Market High Potential Countries, Segments and Strategies

• 35.1 Age-Related Macular Degeneration Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Age-Related Macular Degeneration Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Age-Related Macular Degeneration Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer